A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 May 2018
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms RANGE
- Sponsors Eli Lilly
- 21 Apr 2018 This trial has been completed in Poland.
- 20 Apr 2018 According to an Eli Lilly media release, the company announced additional top-line results from this trial.
- 20 Apr 2018 According to an Eli Lilly media release, efficacy and safety results will be submitted for presentation at a future medical meeting. Internal and external experts will review the data from this trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History